PROGRAM OVERVIEW

Guided by national needs and based on the coordinated development of the Shenzhen Hong Kong Science and Technology Special Zone, we aim to cultivate high-level composite talents in "basic medicine+X" who are innovative and interdisciplinary.

Training objective: To benchmark the major strategic needs of "human health" and grasp the cutting-edge dynamics and development trends in the field of basic medical research; Integrating the characteristics of Shenzhen and Hong Kong, emphasizing interdisciplinary and practical applications, cultivating "basic medicine+X" composite medical professionals with solid basic medical theoretical knowledge and experimental skills, innovative spirit, good scientific and humanistic literacy, independent ability to engage in basic medical education, research and transformation, and international perspective.

CORE COURSES

Design and Writing of Research Projects, Advanced Experimental Techniques, Basic Medical Seminar Courses, Artificial Intelligence Medicine, Frontiers in Infection and Immunology, Frontiers in Medical Cell Biology, Advanced Physiology and Disease, Biochemistry and Molecular Biology, Molecular Pharmacology

CAREER PROSPECTS

Teaching and research positions in higher medical colleges, hospitals, research institutions, biotechnology companies.

Consultation

Email: molmed.hsc@szu.edu.cn                

专业简介

培养定位：以国家需求为导向，立足深港科技特区协同发展，培养“创新基石，学科交叉”的 “基础医学+X”高层次复合型人才。

培养目标：对标“健康中国”重大战略需求，把握基础医学研究领域前沿动态和发展趋势；融合深港特色，注重学科交叉和实践应用，培养具有扎实的基础医学理论知识和实验技能、创新精神、良好的科学人文素养、能够独立从事基础医学教育、研究与转化，具有国际视野的“重基础、精科研、能交叉、会转化”的“基础医学+X”复合型医学专业人才。

核心课程

科研项目设计与撰写、先进实验技术、基础医学seminar课程、人工智能医学、感染与免疫学前沿、医学细胞生物学前沿、高级生理学与疾病、生物化学与分子生物学、分子药理学

就业前景

高等医学院校、医院、科研机构、生物技术公司等教学与研发岗位

咨询方式

Email: molmed.hsc@szu.edu.cn

英文名

Liu Baohua

联系邮箱

Ppliew@szu.edu.cn

中文简介

北京大学学士，香港大学博士，国家杰青、优青、青年特聘专家，广东省优粤人才（A类），深圳市孔雀人才，深圳大学特聘教授，博士生导师，基础医学院院长，校学术委员会副主任（理工医），国家生化工程技术研究中心（深圳）主任，深圳市系统衰老与主动健康重点实验室主任。任亚洲衰老研究学会秘书长，中国老年医学学会基础与转化医学分会副会长，中国生物物理学会衰老生物学专业委员会副会长，中国老年学和老年医学学会老年病学分会常务委员，中国细胞生物学会衰老细胞生物学分会常务委员。主持国家自然科学基金重大项目、香港研究资助局等科研基金，从事衰老机制与干预策略研究，在Nat Med, Cell Metab, Nat Metab, Sci Adv, Nat Commun, EMBO J, Elife 等国际高水平期刊发表学术论文，获教育部自然科学二等奖[2022]、深圳市自然科学一等奖[2022]。

英文简介

Bachelor's degree from Peking University, Ph.D. from the University of Hong Kong, The National Science Fund for Distinguished Young Scholars, Excellent Young Scientists Fund, Guangdong Province Excellent Talent (Category A), Shenzhen Peacock Talent, Distinguished Professor at Shenzhen University, Ph.D. Supervisor, Dean of the School of Basic Medicine, Deputy Director of the Academic Committee of the University(Medical Science and technology), Director of the National Biochemical Engineering Technology Research Center (Shenzhen), and Director of the Shenzhen Key Laboratory of System Aging and Active Health. He has led major projects funded by The National Natural Science Foundation of China and the Hong Kong Research Grants Council, conducting research on aging mechanisms and intervention strategies. He has published academic papers in high-level international journals such as Nat Med, Cell Metab, Nat Metab, Nat Aging, Sci Adv, Nat Commun, EMBO J, and Elife, and has received the Second Prize in Natural Science from the Ministry of Education [2022] and the First Prize in Natural Science from Shenzhen [2022].

英文名

Cai Yi

联系邮箱

Caiyi0113@szu.edu.cn

中文简介

蔡毅，长聘副教授，博士生导师，深圳大学生物安全三级实验室副主任。长期从事结核感染发病机制研究，主要包括：1）结核发生发展与细胞异质性；2）细菌与宿主相互作用的机制；3）抗结核药物筛选及其作用机制；4）结核感染宿主免疫保护机制。研究相关成果发表在Journal of Clinical Investigation，Journal of Experimental Medicine，PLOS Pathogens，mBio等杂志，发明专利11项，转化1项，完成靶向宿主治疗结核病药物SASP临床III期试验。主持国家自然科学4项、深圳市学科布局项目1项、重点项目1项、深圳市医科院一般项目等。相关成果获广东省科技进步奖二等奖，深圳市自然科学二等奖。

英文简介

Dr. Yi Cai is currently an Associate Professor with Tenure in the Department of Pathogenic Biology, Shenzhen University Medical. His research interests lie in host-pathogen interactions and Tuberculosis (TB) disease progression. His primary research areas include: the relationship between cellular heterogeneity and tuberculosis development; the mechanisms of host-pathogen interactions in tuberculosis; screening and mechanisms of anti-tuberculosis drugs; host immune protection mechanisms against tuberculosis infection. His research findings have been published in journals such as Journal of Clinical Investigation, Journal of Experimental Medicine, PLOS Pathogens, and mBio. He holds 11 invention patents, with one successfully commercialized, and has completed a phase III clinical trial for the host-targeted tuberculosis drug SASP. He has led four projects funded by the National Natural Science Foundation of China and several grants from Shenzhen. His work has earned him the Second Prize of the Guangdong Provincial Science and Technology Progress Award and the Second Prize of the Shenzhen Natural Science Award.

英文名

Xue Liu

联系邮箱

xueliu@szu.edu.cn

中文简介

刘雪, 深圳大学医学部副教授，深圳市海外高层次人才，广东省特支计划青年拔尖人才获得者。2021年8月入职深圳大学医学部，组建人类病原性细菌研究团队（http://xliugroup.com/）。近年发表SCI论文20余篇，其中第一作者（含共同一作）论文10篇，包括Cell Host & Microbe, Molecular Cell, Nature Protocols, Molecular Systems Biology (封面文章）等国际知名高水平期刊。首次鉴定了LafB可为广谱的链球菌菌的疫苗靶点，并获国际专利1项。

“克菌治病”课题组目前研究方向包括以下三个方面：

1） 重要人类病原细菌的致病机理。

2） 肠道非模式细菌的高效遗传筛选平台开发。

3)  采用时空组学探究细菌感染关键病灶的发病机制。

英文简介

Liu Xue is an associate professor at the Medical School of Shenzhen University, a high-level overseas talent in Shenzhen, and a recipient of the Guangdong Province Special Support Program for Young Talents. In August 2021, she joined the Medical School of Shenzhen University and established the Human Pathogenic Bacteria Research Team (http://xliugroup.com/). In recent years, she has published more than 20 SCI papers, including 9 as the first author or co-first author, in internationally renowned high-level journals such as Cell Host & Microbe, Molecular Cell, Nature Protocols, and Molecular Systems Biology (cover article). She identified LafB as a target for pneumococcal vaccine develop with wide-range protection against strains with different serotypes.

Our "Fighting Bacterial Diseases" research group is currently focused on three main areas:

1) The pathogenic mechanisms of important bacterial human pathogens.

2) The development of efficient genetic screening platforms for non-model bacteria in the gut.

3) Using spatial and temporal omics to explore the pathogenesis of key lesions in bacterial infections.

英文名

Huiqiang Lou

联系邮箱

lou@szu.edu.cn

中文简介

 楼慧强，博士，深圳大学医学部特聘教授。1997年本科毕业于北京大学生命科学学院，2004年博士毕业于中国科学院微生物研究所。2004-2009年在加州理工学院先后从事博士后、CIRM fellow 工作，2009-2020年中国农业大学生物学院教授、博导，历任微生物学与免疫学系系主任、科研副院长、农业生物技术国家重点实验室副主任。担任中国微生物学会理事、《微生物学报》、《mLife》、《Engineering Microbiology》编委。

主要从事糖代谢与DNA复制研究。主持国家自然科学基金重点项目1项、面上项目4项、参与国家“重点研发”重大专项子课题1项。近5年以通讯作者在Gen & Dev、EMBO Rep、CMLS、Cell Rep、PLoS Genet等杂志发表论文30余篇；获得国家发明专利2项，申请PCT专利2项。

英文简介

The Lou Group is devoted to uncover the potential crosstalk between metabolic dysregulation and genome instability, the two major resources which are considered to underlie cancer initiation. We apply multidisciplinary approaches such as genetics, biochemistry, cell biology, quantitative biology and synthetic biology to investigate DNA replication, co-replication events and whether/how sugar metabolism affects DNA replication/genome integrity. Our recent high-impact publications include Genes & Dev, EMBOJ, Cell Rep, EMBO Rep, CMLS, PLoS Genet.  

英文名

Sisi Li

联系邮箱

liss@szu.edu.cn

中文简介

2013年获复旦大学博士学位，随后加入纽约纪念斯隆凯特琳癌症中心（MSKCC）从事博士后研究。2016-2021年任南方科技大学生物系研究副教授，2021年加入深圳大学卡尔森国际肿瘤中心任特聘教授。 国家级青年人才，深圳市杰出青年人才。

李思思博士近年来专注RNA转录后调控的机制研究，通过多种生物学研究手段，建立从RNA的化学结构，到RNA与相关蛋白质的调控机制与生理功能，最后到RNA药物开发的联合体系。近五年来以第一或通讯（含共同）作者身份在Science、 Nat Commun和 PNAS等学术期刊上发表学术论文十余篇，部分研究成果获同期专评，以及学术媒体Faculty Opinion的推荐，并担任多个知名期刊的审稿人。

英文简介

Dr. Li Sisi obtained her Ph.D. degree from Fudan University in 2013, and joined the Memorial Sloan Kettering Cancer Center in New York for postdoctoral research. From 2016 to 2021, she was an Associate Professor at the Department of Biology at Southern University of Science and Technology, and in 2021, she joined the Carlson International Cancer Center at Shenzhen University as professor. She was awarded the National Science Foundation for Outstanding Young Scholars and Outstanding Young Talents of Shenzhen.

In recent years, Dr. Li has focused on the mechanisms of RNA post-transcriptional regulation. Using various biological research methods, she has established a joint system from the chemical structure of RNA to the regulation mechanism and physiological function of RNA with relevant proteins, and finally to RNA drug development. In the past five years, she has published over ten academic papers as the first or corresponding author in high-profile journals such as Science, Nature Communications, and PNAS. Some of her research achievements have received specialized reviews and recommendations from academic media such as Faculty Opinion, and she has also served as a reviewer for several well-known journals.

英文名

Yin Peng

联系邮箱

ypeng@szu.edu.cn

中文简介

2010年毕业于Loyola University Chicago获生物医学博士学位。现任深圳大学医学部病理学系副教授。主要研究方向是胃肠道肿瘤中的非编码RNA作用机制及其相关信号通路，发表SCI一作和通讯作者论文20篇，包括 Oncogene，Molecular Cancer，Cancer Letters等。主持国家自然科学基金2项、广东省自然科学基金2项及广东省医学科学基金，深圳市基础研究，深圳高层次人才基金，深圳大学启动基金等多个项目，总经费超过500万。美国肿瘤学会AACR会员。深圳市孔雀C类人才。

英文简介

Dr. Yin Peng received the PhD degree in Molecular and Cellular Biochemistry from Loyola University Chicago in 2010. She is currently an associate professor in Department of Pathology at Shenzhen University, China. Her long-standing research interests lie in elucidating the molecular mechanisms of cell signaling transduction pathway underlying tumorigenesis. Her lab is actively exploring how oncogenic circRNAs regulate critical signaling transduction pathways, such as the Wnt/β -catenin pathway and NF-κB signaling pathway to promote cell survival, proliferation and migration in cancer cells. She has published over 20 first author/corresponding author papers in professional, peer-reviewed journals including Oncogene, Molecular Cancer, Cancer Letters. She is an AACR member and Shenzhen Peacock Talent C.